DOTHAN, Ala. (November 6, 2025) — Cencora, a global leader in pharmaceutical distribution and healthcare logistics, has announced a sweeping $1 billion investment to modernize and expand its U.S. operations over the next five years. Central to this initiative is a major expansion of Cencora’s Dothan, Alabama facility, positioning the city as a key hub in the nation’s pharmaceutical supply chain.
The investment aims to bolster cold-chain logistics, automate distribution centers, and enhance delivery efficiency amid growing demand for specialty drugs that require precise temperature control and advanced handling.
Transforming the Dothan Facility into a Cold-Chain Powerhouse
Cencora’s Dothan hub—vital for managing temperature-sensitive therapies—will undergo a transformative upgrade set for completion in fall 2026. The project will expand refrigerated storage by 500% and frozen capacity by 200%, dramatically increasing the facility’s ability to manage complex biologics and specialty pharmaceuticals.
“Frontline healthcare heroes count on us to bridge the gap between vital prescriptions and those who need them most,” said Bob Mauch, President and CEO of Cencora. “This investment is more than capital allocation—it’s a pledge to build a bulletproof supply chain that ensures equitable, on-time access to life-saving therapies, no matter the location.”
The Dothan expansion underscores Alabama’s growing prominence in the national healthcare logistics sector and reaffirms Cencora’s role as a trusted partner to providers nationwide.
Nationwide Network Modernization: Ohio and California Expansions
Beyond Alabama, Cencora’s $1 billion commitment includes two additional U.S. megaprojects:
- Harrison, Ohio: A 530,000-square-foot national distribution center, slated to open spring 2027, will feature AI-driven robotics and autonomous logistics systems designed to maximize throughput and scalability.
- Fontana, California: A 430,000-square-foot West Coast facility, nearly double the size of its predecessor, will open fall 2026, further enhancing the company’s reach across the Pacific region with next-generation automation.
These advancements will position Cencora to manage the rising wave of specialty drug distribution, projected to represent 70% of all new launches by 2027, half of which will require specialized cold-chain capabilities.
Driving Innovation and Reliability Across U.S. Healthcare
“Our north star is service excellence — built on understanding our clients, anticipating trends, and investing in what’s next,” said Rich Tremonte, Executive Vice President and President of U.S. Pharmaceuticals and Animal Health at Cencora. “With specialty pipelines accelerating, these expansions will empower providers to deliver exceptional care right in their communities.”
Cencora’s U.S. network currently ships more than five million doses and healthcare products daily to thousands of hospitals, pharmacies, and healthcare facilities, serving as a critical backbone of the nation’s healthcare ecosystem.
About Cencora
Cencora (NYSE: CORA) is a Fortune 500 and Global Fortune 500 company, ranking #10 and #18 respectively, with annual revenues exceeding $300 billion. Headquartered in Conshohocken, Pennsylvania, Cencora delivers pharmaceutical, logistics, and supply chain solutions that improve patient access and elevate healthcare outcomes globally.
With a team of over 51,000 professionals worldwide, Cencora collaborates across the healthcare continuum—from laboratory innovators to frontline providers—to ensure secure, efficient, and reliable delivery of therapies to patients everywhere.
Learn more at Cencora.com.
